ArticleOncoTargets and therapy2022

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.

Yingchao Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.